The Effects of Psychological Interventions on Diabetic Peripheral Neuropathy: A Systematic Review and Meta-Analysis

Racaru, Simona; Sturt, Jackie; Çelik, Aycan

doi:10.1016/j.pmn.2020.11.001

Cited by 6 publications

(5 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to the evaluation of treatments, 11SRs [ 37 – 47 ] only evaluated CBT-related techniques, 11 SRs [ 34 , 48 – 57 ] also evaluated other psychological therapies, 5 SRs [ 58 – 62 ] evaluated nonpharmacological interventions in addition to psychological therapies, 2 SRs [ 35 , 63 ] evaluated pharmacological and nonpharmacological interventions, and 5 SRs [ 36 , 64 – 67 ] evaluated various interventions. Of the available data, 15 SRs [ 38 – 40 , 43 – 45 , 47 , 50 , 53 – 57 , 63 , 65 ] included migraine, 7 SRs [ 34 , 35 , 52 , 60 , 64 , 66 , 67 ] included burning mouth syndrome, 4 SRs [ 36 , 42 , 46 , 62 ] included cancer-related neuropathic pain, 3 SRs [ 51 , 59 , 61 ] included diabetic peripheral neuropathy, 3 SRs [ 48 , 49 , 58 ] included pain after spinal cord injury, and 2 SRs [ 37 , 41 ] included patients with NP of different causes.…”

Section: Resultsmentioning

confidence: 99%

“…According to the AMSTAR-2 scoring criteria ( Figure 3 ), 2 SRs were rated “high.” 2 SRs were rated “moderate,” 6 SRs were rated “low,” and 24 SRs were rated “critically low.” The main reasons for downgrading the SRs were as follows: there was no protocol reported before the review or no explanation for differences from protocol [ 35 – 38 , 42 – 47 , 51 , 52 , 55 – 57 , 61 , 65 – 67 ]; there was no list of excluded studies and reasons for exclusion [ 34 – 37 , 39 , 40 , 42 , 43 , 45 – 47 , 51 , 55 – 57 , 59 – 62 , 65 – 67 ]; there was no explanation for the study design included in the SRs [ 34 – 42 , 45 – 53 , 55 , 57 – 62 , 64 – 67 ]; there was no report of funding sources for studies included in the SRs [ 35 – 47 , 50 , 51 , 55 – 58 , 60 – 62 , 65 – 67 ]; the risk bias of the included studies was not considered when interpreting or discussing the study results [ 35 – 38 , 40 , 43 , 46 , 47 , 50 , 51 , 56 , 57 , 59 , 62 , 63 , 66 ]; the publication bias was not adequately investigated when quantitative synthesis...…”

Section: Resultsmentioning

confidence: 99%

“…Three SRs [34][35][36] did not fully report characteristics, including search date, design of included studies, and participants. According to the evaluation of treatments, 11SRs [37][38][39][40][41][42][43][44][45][46][47] only evaluated CBT-related techniques, 11 SRs [34,[48][49][50][51][52][53][54][55][56][57]] also evaluated other psychological therapies, 5 SRs [58][59][60][61][62] [38-40, 43-45, 47, 50, 53-57, 63, 65] included migraine, 7 SRs [34,35,52,60,64,66,67] included burning mouth syndrome, 4 SRs [36,42,46,62] included cancer-related neuropathic pain, 3 SRs [51,59,61] included diabetic peripheral neuropathy, 3 SRs [48,49,…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Evidence Mapping Based on Systematic Reviews of Cognitive Behavioral Therapy for Neuropathic Pain

Hou

Ding

et al. 2023

Neural Plasticity

View full text Add to dashboard Cite

Objective. This evidence mapping is aimed at identifying, summarizing, and analyzing the available evidence on cognitive behavioral therapy (CBT) for neuropathic pain (NP). Methods. This study was conducted following the methodology of Global Evidence Mapping (GEM). Searches were conducted in PubMed, Embase, the Cochrane Library, and PsycINFO to identify systematic reviews (SRs) with or without meta-analysis published before February 15, 2022. The authors independently assessed eligibility, extracted data, and evaluated the methodological quality of the included SRs using AMSTAR-2. The results were presented in the tables and a bubble plot based on the identified population-intervention-comparison-outcome (PICO) questions. Results. A total of 34 SRs met the eligibility criteria. According to the AMSTAR-2, 2 SRs were rated “high,” 2 SRs were rated “moderate,” 6 SRs were rated “low,” and 24 SRs were rated “critically low.” The most common study design utilized to evaluate the efficacy of CBT for NP was the randomized controlled trial. In total, 24 PICOs were identified. Migraine was the most studied population. CBT for NP usually reaches the “potentially better” result at follow-up. Conclusions. Evidence mapping is a useful way to present existing evidence. Currently, the existing evidence on CBT for NP is limited. Overall, the methodological quality of the included SRs was low. Further improvements in the methodological quality of SRs and more research on the most efficient CBT formats for NP are recommended in the future.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Evidence Mapping Based on Systematic Reviews of Cognitive Behavioral Therapy for Neuropathic Pain

Hou

Ding

et al. 2023

Neural Plasticity

View full text Add to dashboard Cite

show abstract

“…Psychological interventions such as mindfulness-based stress reduction and cognitive behavioral therapy can also have a significant beneficial effect on pain severity, pain interference, depressive symptoms, and quality of life in patients with DPN ( 164 ).…”

Section: Management Of Diabetic Peripheral Neuropathymentioning

confidence: 99%

Expert opinion on screening, diagnosis and management of diabetic peripheral neuropathy: a multidisciplinary approach

Atmaca,

Ketenci,

Sahin

et al. 2024

Front. Endocrinol.

View full text Add to dashboard Cite

The proposed expert opinion aimed to address the current knowledge on conceptual, clinical, and therapeutic aspects of diabetic peripheral neuropathy (DPN) and to provide a guidance document to assist clinicians for the best practice in DPN care. The participating experts consider the suspicion of the disease by clinicians as a key factor in early recognition and diagnosis, emphasizing an improved awareness of the disease by the first-admission or referring physicians. The proposed “screening and diagnostic” algorithm involves the consideration of DPN in a patient with prediabetes or diabetes who presents with neuropathic symptoms and/or signs of neuropathy in the presence of DPN risk factors, with careful consideration of laboratory testing to rule out other causes of distal symmetric peripheral neuropathy and referral for a detailed neurological work-up for a confirmative test of either small or large nerve fiber dysfunction in atypical cases. Although, the first-line interventions for DPN are currently represented by optimized glycemic control (mainly for type 1 diabetes) and multifactorial intervention (mainly for type 2 diabetes), there is a need for individualized pathogenesis-directed treatment approaches for DPN. Alpha-lipoic acid (ALA) seems to be an important first-line pathogenesis-directed agent, given that it is a direct and indirect antioxidant that works with a strategy targeted directly against reactive oxygen species and indirectly in favor of endogenous antioxidant capacity for improving DPN conditions. There is still a gap in existing research in the field, necessitating well-designed, robust, multicenter clinical trials with sensitive endpoints and standardized protocols to facilitate the diagnosis of DPN via a simple and effective algorithm and to track progression of disease and treatment response. Identification of biomarkers/predictors that would allow an individualized approach from a potentially disease-modifying perspective may provide opportunities for novel treatments that would be efficacious in early stages of DPN, and may modify the natural course of the disease. This expert opinion document is expected to increase awareness among physicians about conceptual, clinical, and therapeutic aspects of DPN and to assist them in timely recognition of DPN and translating this information into their clinical practice for best practice in the management of patients with DPN.

show abstract

“…Many studies have demonstrated that psychotherapies 302 – including CBT 303‐305 , mindfulness‐based interventions 306‐308 , compassion‐focused therapies 309,310 and problem‐solving therapy 311 – effectively treat MDD in people with diseases such as cancer 307,308 , diabetes mellitus 312,313 , cardiovascular diseases 314‐318 , HIV infection 319 , psoriasis 320 , multiple sclerosis 279,321,322 , inflammatory bowel disease 305 , chronic obstructive pulmonary disease 323‐325 , and kidney failure 326‐328 .…”

Section: Clinical Managementmentioning

confidence: 99%

Comorbidity between major depressive disorder and physical diseases: a comprehensive review of epidemiology, mechanisms and management

Berk,

Köhler‐Forsberg,

Turner

et al. 2023

World Psychiatry

View full text Add to dashboard Cite

Populations with common physical diseases – such as cardiovascular diseases, cancer and neurodegenerative disorders – experience substantially higher rates of major depressive disorder (MDD) than the general population. On the other hand, people living with MDD have a greater risk for many physical diseases. This high level of comorbidity is associated with worse outcomes, reduced adherence to treatment, increased mortality, and greater health care utilization and costs. Comorbidity can also result in a range of clinical challenges, such as a more complicated therapeutic alliance, issues pertaining to adaptive health behaviors, drug‐drug interactions and adverse events induced by medications used for physical and mental disorders. Potential explanations for the high prevalence of the above comorbidity involve shared genetic and biological pathways. These latter include inflammation, the gut microbiome, mitochondrial function and energy metabolism, hypothalamic‐pituitary‐adrenal axis dysregulation, and brain structure and function. Furthermore, MDD and physical diseases have in common several antecedents related to social factors (e.g., socioeconomic status), lifestyle variables (e.g., physical activity, diet, sleep), and stressful live events (e.g., childhood trauma). Pharmacotherapies and psychotherapies are effective treatments for comorbid MDD, and the introduction of lifestyle interventions as well as collaborative care models and digital technologies provide promising strategies for improving management. This paper aims to provide a detailed overview of the epidemiology of the comorbidity of MDD and specific physical diseases, including prevalence and bidirectional risk; of shared biological pathways potentially implicated in the pathogenesis of MDD and common physical diseases; of socio‐environmental factors that serve as both shared risk and protective factors; and of management of MDD and physical diseases, including prevention and treatment. We conclude with future directions and emerging research related to optimal care of people with comorbid MDD and physical diseases.

show abstract

The Effects of Psychological Interventions on Diabetic Peripheral Neuropathy: A Systematic Review and Meta-Analysis

Cited by 6 publications

References 27 publications

Evidence Mapping Based on Systematic Reviews of Cognitive Behavioral Therapy for Neuropathic Pain

Evidence Mapping Based on Systematic Reviews of Cognitive Behavioral Therapy for Neuropathic Pain

Expert opinion on screening, diagnosis and management of diabetic peripheral neuropathy: a multidisciplinary approach

Comorbidity between major depressive disorder and physical diseases: a comprehensive review of epidemiology, mechanisms and management

Contact Info

Product

Resources

About